Cystic Fibrosis Clinical Trials

This Study will not provide or recommend any treatment or any changes to your standard medical care. If you participate, there will not be any additional doctor visits outside of your standard medical visits to the Cystic Fibrosis Care Centers. Participation in this Study will not require any additional time ...

The purpose of this clinical research study is to evaluate the safety and effectiveness of an experimental drug as a treatment for non-CF bronchiectasis and to measure the concentration of the experimental drug in the blood after treatment.

PART 1 The SAD treatment group is comprised of three cohorts where HV will be randomized to either PTI-801 or placebo. Following the conclusion of at least three SAD cohorts, a set of HV will participate in an assigned MAD treatment group. The MAD treatment group is comprised of three ...

This is an observational, translational study examined bacterial morphology and function prevs. post antibiotic therapy in patients with CF who experience a pulmonary exacerbation that requires IV antibiotics. All clinical care is dictated by the treating physician(s). Inclusion criteria: Male or female with a confirmed diagnosis of CF (by sweat ...

This is an open-label, non-randomised, single-sequence 2-part study. Enrolment into Part 2 of the study will begin after Part 1 is complete, and a review of safety and pharmacokinetic data has been completed.Part 1 will assess the safety, tolerability and pharmacokinetics of single doses of FDL176 with and without co-administration ...

This is a Phase III, randomized, multicenter, double-blind, placebo-controlled, parallel-group study to examine the safety and efficacy of AeroVanc in the treatment of persistent Methicillin resistant Staphylococcus aureus (MRSA) lung infection in patients diagnosed with cystic fibrosis (CF). After the Screening period to confirm study eligibility, subjects will be randomly ...

Numerous studies have demonstrated that patients with chronic illnesses are at increased risk for depression and anxiety. In large, well-controlled epidemiological studies, rates of depression in medical populations have ranged from 17% to 50% compared to 5% to 17.5% in healthy populations. Reporting on a community-based sample, Wells and colleagues ...

Cystic Fibrosis related diabetes (CFRD), a major factor of morbid-mortality in CF, is characterized by a preclinical phase of glucose intolerance particularly long reaching up to 10 years. At the physiopathology level, insulin secretion is determinant in the glucose tolerance abnormalities in CF. Indeed insulin secretion is dependent of the ...

Pulmonary inflammation is an independent risk factor for disease progression in cystic fibrosis patients (CF). Yet, no effective treatment is known to reduce this detrimental inflammation. Dysbiosis of the gut microbiota has been linked to inflammation in several inflammatory diseases. As children with CF have different faecal microbiota from their ...

After completing the study inclusion criteria, the individual will be invited to participate and will receive the consent form for signature. The patient will be submitted to the following evaluations: quality of life questionnaire for cystic fibrosis, spirometry, Shwachman-Kulczycki score, modified dyspnea questionnaire (Modified Medical Research Council), maximum repetition test, ...